Zymeworks (ZYME) Competitors $18.62 +0.39 (+2.14%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$18.49 -0.13 (-0.70%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. ARWR, ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, and MIRMShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Arrowhead Pharmaceuticals Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Zymeworks (NYSE:ZYME) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do institutionals & insiders believe in ZYME or ARWR? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to ZYME or ARWR? In the previous week, Zymeworks had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 19 mentions for Zymeworks and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.79 beat Zymeworks' score of 0.59 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ZYME or ARWR? Zymeworks has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Do analysts recommend ZYME or ARWR? Zymeworks presently has a consensus target price of $24.13, suggesting a potential upside of 29.56%. Arrowhead Pharmaceuticals has a consensus target price of $43.14, suggesting a potential upside of 12.97%. Given Zymeworks' stronger consensus rating and higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Arrowhead Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78 Is ZYME or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Arrowhead Pharmaceuticals N/A -40.91%-11.62% Which has stronger valuation and earnings, ZYME or ARWR? Zymeworks has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M11.39-$118.67M-$0.97-19.20Arrowhead Pharmaceuticals$3.55M1,487.37-$599.49M-$1.28-29.84 SummaryZymeworks beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.37B$1.06B$6.12B$21.89BDividend YieldN/A4.84%5.73%3.62%P/E Ratio-12.411.2585.3330.12Price / Sales11.3931.47601.99108.95Price / CashN/A17.6437.4624.26Price / Book2.817.6612.564.70Net Income-$118.67M-$7.71M$3.32B$1.01B7 Day Performance10.05%-0.76%0.59%0.49%1 Month Performance17.55%24.34%10.52%1.61%1 Year Performance37.93%-12.21%75.05%13.30% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.3329 of 5 stars$18.62+2.1%$24.13+29.6%+33.7%$1.37B$122.87M-12.41460Analyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.8677 of 5 stars$37.50+3.8%$43.14+15.0%+92.1%$4.99B$3.55M-29.30400ACLXArcellx1.8566 of 5 stars$84.38-0.8%$114.31+35.5%+2.7%$4.72B$107.94M-24.6780Analyst RevisionKYMRKymera Therapeutics1.3788 of 5 stars$57.55-0.6%$61.26+6.5%+40.4%$4.14B$47.07M-16.58170Insider TradePTGXProtagonist Therapeutics1.7197 of 5 stars$64.14-1.1%$68.36+6.6%+63.1%$4.03B$209.18M91.63120Analyst ForecastInsider TradeGap DownCRNXCrinetics Pharmaceuticals3.7522 of 5 stars$41.68+2.0%$74.45+78.6%-23.4%$3.85B$1.04M-10.14210ZLABZai Lab2.7845 of 5 stars$33.31-1.3%$56.35+69.2%+18.6%$3.77B$398.99M-16.331,869News CoverageAKROAkero Therapeutics3.6944 of 5 stars$46.04-0.1%$81.14+76.2%+79.1%$3.69BN/A-23.0230Insider TradeACADACADIA Pharmaceuticals4.5235 of 5 stars$21.59-1.0%$29.12+34.9%+45.8%$3.68B$1.02B16.23510Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600Gap UpMIRMMirum Pharmaceuticals2.9089 of 5 stars$72.53-0.6%$76.50+5.5%+91.9%$3.66B$336.89M-59.94140Analyst Revision Related Companies and Tools Related Companies ARWR Alternatives ACLX Alternatives KYMR Alternatives PTGX Alternatives CRNX Alternatives ZLAB Alternatives AKRO Alternatives ACAD Alternatives AAPG Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
